Rauch MC, San Martin A, Ojeda D et al (2009) Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects. Transpl Immunol 22(1–2):72–81

Wu B, Tong J, Ran Z (2020) Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis 26(1):24–32

Article  PubMed  Google Scholar 

Hao GX, Song LL, Zhang DF et al (2020) Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. Br J Clin Pharmacol 86(2):274–284

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ong SC, Gaston RS (2021) Thirty Years of Tacrolimus in Clinical Practice. Transplantation 105(3):484–495

Article  CAS  PubMed  Google Scholar 

Sikma MA, van Maarseveen EM, van de Graaf EA et al (2015) Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. Am J Transplant 15(9):2301–2313

Article  CAS  PubMed  Google Scholar 

Yu M, Liu M, Zhang W et al (2018) Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. Curr Drug Metab 19(6):513–522

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shuker N, van Gelder T, Hesselink DA (2015) Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando) 29(2):78–84

Article  PubMed  Google Scholar 

Lu YX, Su QH, Wu KH et al (2015) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin 36(2):281–288

Article  CAS  PubMed  Google Scholar 

Li CJ, Li L (2015) Tacrolimus in preventing transplant rejection in Chinese patients–optimizing use. Drug Des Devel Ther 9(1):473–485

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mercè B, Teun VG, Anders Å et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41(3):261–307

Abdel Jalil M, Abdullah N, Alsous M et al (2021) Population pharmacokinetic studies of digoxin in adult patients: a systematic review. Eur J Drug Metab Pharmacokinet 46(3):325–342

Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2(4):e38

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brooks E, Tett SE, Isbel NM et al (2016) Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? Clin Pharmacokinet 55(11):1295–1335

Article  CAS  PubMed  Google Scholar 

Campagne O, Mager DE, Tornatore KM (2019) Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? J Clin Pharmacol 59(3):309–325

Article  CAS  PubMed  Google Scholar 

Kirubakaran R, Stocker SL, Hennig S et al (2020) Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clin Pharmacokinet 59(11):1357–1392

Article  CAS  PubMed  Google Scholar 

Nanga TM, Doan TTP, Marquet P et al (2019) Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. Br J Clin Pharmacol 85(12):2793–2823

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jahan A, Prabha R, Chaturvedi S et al (2015) Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 30(11):1961–1967

Article  PubMed  Google Scholar 

Lingfei H, Junyan W, Jufei Y et al (2019) Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. Pharmacogenomics 20(15):1071–1083

Article  Google Scholar 

Wang J, Huang L, Gao P et al (2021) Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. Eur J Clin Pharmacol 77(1):71–77

Article  CAS  PubMed  Google Scholar 

Zhu L, Yang J, Zhang Y et al (2015) Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. Xenobiotica 45(9):840–846

Article  CAS  PubMed  Google Scholar 

Ji E, Kim MG, Oh JM (2018) CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 14(10):2119–2126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antignac M, Barrou B, Farinotti R et al (2007) Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 64(6):750–757

CAS  PubMed  PubMed Central  Google Scholar 

Tuteja S, Alloway RR, Johnson JA et al (2001) The effect of gut metabolism on tacrolimus bioavailability in renaltransplant recipients1,2. Transplantation 71(9):1303–1307

Article  CAS  PubMed  Google Scholar 

Kanji S, Hayes M, Ling A et al (2015) Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet 54(7):783–795

Article  PubMed  Google Scholar 

Dartois C, Brendel K, Comets E et al (2007) Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol 64(5):603–612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdel Jalil MH, Abdullah N, Alsous MM et al (2020) A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. Br J Clin Pharmacol 86(7):1267–1280

Li Z-R, Wang C-Y, Zhu X et al (2021) Population pharmacokinetics of levetiracetam: a systematic review. Clin Pharmacokinet 60(3):305–318

Minghao L, Minglu W, Xu Z et al (2022) Tacrolimus Population Pharmacokinetic Model in Adult Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo Simulations. Ther Drug Monit 44(5):615–624

Article  Google Scholar 

Li L, Zhu M, Li DY et al (2021) Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. Int Immunopharmacol 98(9):107827

Article  CAS  PubMed  Google Scholar 

Chen X, Wang D, Xu H et al (2020) Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule. J Clin Pharm Ther 45(2):309–317

Article  PubMed  Google Scholar 

Chen X, Wang DD, Xu H et al (2020) Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule. Xenobiotica 50(5):606–613

Article  CAS  PubMed  Google Scholar 

Lu T, Zhu X, Xu S et al (2019) Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome. Pharm Res 36(3):45

Article  CAS  PubMed  Google Scholar 

Chen X, Wang D, Xu H et al (2020) Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real world data. Exp Ther Med 20(2):1423–1430

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang D, Chen X, Xu H et al (2019) Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations. Exp Ther Med 18(6):4653–4660

CAS  PubMed  PubMed Central  Google Scholar 

Wang D, Lu J, Li Q et al (2019) Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. Exp Ther Med 17(5):4023–4031

CAS  PubMed  PubMed Central  Google Scholar 

Huang Q, Lin X, Wang Y et al (2022) Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction. Front Pharmacol 13(11):942129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang DD, Lu JM, Li Q et al (2018) Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther 43(4):476–483

Article  CAS  PubMed  Google Scholar 

Huang L, Liu Y, Jiao Z et al (2020) Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 143(1):105199

Article  CAS  PubMed  Google Scholar 

Wang X, Han Y, Chen C et al (2019) Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome. Int J Clin Pharmacol Ther 57(3):125–134

Article  CAS  PubMed  Google Scholar 

Hao GX, Huang X, Zhang DF et al (2018) Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol 84(8):1748–1756

Article  CAS  PubMed  PubMed Central